Financial Services -
Asset Management - NYSE - US
$ 16.6
-3.43 %
$ 2.87 B
Market Cap
10.31
P/E
1. INTRINSIC VALUE
Balance Sheet
Hercules Capital, Inc.
| Current Assets | 75.3 M |
| Cash & Short-Term Investments | 42.7 M |
| Receivables | 32.6 M |
| Other Current Assets | 0 |
| Non-Current Assets | 16.8 M |
| Long-Term Investments | 0 |
| PP&E | 16.8 M |
| Other Non-Current Assets | 0 |
| Current Liabilities | 73.1 M |
| Accounts Payable | 54.9 M |
| Short-Term Debt | 18.2 M |
| Other Current Liabilities | 0 |
| Non-Current Liabilities | 1.82 B |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 1.82 B |
EFFICIENCY
Earnings Waterfall
Hercules Capital, Inc.
| Revenue | 416 M |
| Cost Of Revenue | 54.2 M |
| Gross Profit | 362 M |
| Operating Expenses | 124 M |
| Operating Income | 237 M |
| Other Expenses | 206 M |
| Net Income | 31.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Hercules Capital, Inc.
| Net Income | 31.5 M |
| Depreciation & Amortization | 31.2 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 12.5 M |
| Change in Working Capital | 0 |
| Others | -178 M |
| Free Cash Flow | -118 M |
Wall Street Analysts Price Targets
Hercules Capital, Inc.
Wall Street analysts predict an average 1-year price target for HTGC of $21.2 , with forecasts ranging from
a
low of
$20 to a high of $22 .
HTGC Lowest Price Target
Wall Street Target
20 USD
20.48%
HTGC Average Price Target
Wall Street Target
21.2 USD
27.51%
HTGC Highest Price Target
Wall Street Target
22 USD
32.53%
4. DIVIDEND
ANALYSIS
6.80%
DIVIDEND YIELD
0.47 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Hercules Capital, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.96 M USD 1
9-12 MONTHS
295 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
500 K USD 6
6-9 MONTHS
14.1 K USD 1
9-12 MONTHS
7. News
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.
globenewswire.com
- 2 weeks ago
Hercules Capital (HTGC) Stock Declines While Market Improves: Some Information for Investors
Hercules Capital (HTGC) closed at $19.06 in the latest trading session, marking a -0.21% move from the prior day.
zacks.com
- 2 weeks ago
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara's balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a tre.
businesswire.com
- 3 weeks ago
Hercules Capital (HTGC) Advances But Underperforms Market: Key Facts
Hercules Capital (HTGC) reachead $19.32 at the closing of the latest trading day, reflecting a +0.42% change compared to its last close.
zacks.com
- 3 weeks ago
Hercules Capital: It Can't Be Missing From Any Dividend Portfolio
Hercules Capital is one of the best BDC with a 20-year history, offering a 10.4% dividend yield and a +1,040% total return since inception. HTGC's strong financials, including recent record-high TII and NII, ensure sustainable dividends and long-term stability. The recent 19% pullbacks give a decent buy signal, despite the stock's premium P/NAV valuation.
seekingalpha.com
- 4 weeks ago
My Favorite Stocks to Add Right Now
A friend of mine keeps posting every day about how much money she has lost in the stock market. I finally had to comment on her post: “Stop checking your account.
etftrends.com
- 4 weeks ago
Is It Worth Investing in Hercules Capital (HTGC) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
zacks.com
- 1 month ago
Hercules Capital: Buy The Drop On This Income Machine
Hercules Capital offers a compelling buy-the-dip opportunity for income investors with a 10% dividend yield and strong earnings yield. HTGC's internally managed structure enhances shareholder alignment and cost efficiency, supporting consistently high returns and a high-quality, predominantly first-lien portfolio. Despite recent market volatility, HTGC maintains low non-accrual rates, strong dividend coverage, conservative leverage, and robust liquidity.
seekingalpha.com
- 1 month ago
Hercules Capital (HTGC) Surpasses Market Returns: Some Facts Worth Knowing
The latest trading day saw Hercules Capital (HTGC) settling at $18.84, representing a +1.78% change from its previous close.
zacks.com
- 1 month ago
Forget Growth: 5 Big Safe Yields Worth Considering
The stock market has been ugly (particularly growth stocks), and it could get much worse. Thankfully, however, there is another way. Income investing focuses on big, steady dividend and interest payments, thereby allowing investors to worry far less about price volatility (as long as those big income payments keep coming in). This report shares 5 big safe yield strategies (including a variety of top income ideas), and then concludes with an important takeaway about succeeding in this market.
seekingalpha.com
- 1 month ago
2 Income ETFs To Ride Out The Current Market Decline
Dividends provide stability and psychological benefits during market declines, helping investors avoid panic selling and irrational decisions. Janus Henderson AAA CLO ETF offers a 6.1% dividend yield with investment-grade debt, providing stable income and sector diversification. Putnam BDC Income ETF offers a 9.1% dividend yield with high-quality BDCs, combining capital appreciation and income, but with higher price volatility.
seekingalpha.com
- 1 month ago
An Important Warning For BDC Investors
Why BDCs may be entering a dangerous phase. Avoid these risks before it's too late. One BDC stands out as a safe bet, and is my top pick right now.
seekingalpha.com
- 1 month ago
8. Profile
Summary
Hercules Capital, Inc. HTGC
COUNTRY
US
INDUSTRY
Asset Management
MARKET CAP
$ 2.87 B
Dividend Yield
6.80%
Description
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
Contact
400 Hamilton Avenue, Palo Alto, CA, 94301
https://www.htgc.com
IPO
Date
June 9, 2005
Employees
100
Officers
Mr. Scott Bluestein
Chief Executive Officer, Chief Investment Officer, President & Director
Ms. Kate Kinlin
Vice President of Human Resources
Mr. Michael Bowden
Managing Director of Portfolio Management
Mr. Roy Y. Liu
Managing Director
Ms. Kiersten Zaza Botelho
Corporate Secretary, Chief Legal & Compliance Officer
Mr. R. Bryan Jadot
Senior MD & Group Head of Life Sciences
Mr. Michael W. Hara
Managing Director of Investor Relations & Corporate Communications
Mr. Seth Hardy Meyer
Chief Financial Officer & Chief Accounting Officer
Mr. Christian Follmann
Chief Operating Officer
Mr. Steve Kuo
Senior MD & Group Head of Technology